-
1 month ago | 
urologytimes.com | Rana R. McKay |Hannah Clarke
In a recent interview with Urology Times®, Rana R. McKay, MD, FASCO, shares the background and key findings from the study, “Real-world persistence and adherence to relugolix (REL) in US patients with nonmetastatic (nm) vs metastatic (m) prostate cancer (PC).”1 This study was presented at the 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco, California.
-
1 month ago | 
urologytimes.com | Rana R. McKay |Hannah Clarke
Radium-223 was FDA approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases in 2013. Since then, the treatment landscape for mCRPC has changed significantly. In the following video, Rana R. McKay, MD, FASCO, shares insight on findings from a systematic literature review of 48 real-world studies assessing radium-223 in mCRPC.
-
Dec 13, 2024 | 02741-6/abstract?rss=yes&sz=64)
europeanurology.com | Rana R. McKay |Joshua Lang |Himisha Beltran
Platinum Priority – Editorial | Referring to the article published on pp.
-
Nov 21, 2024 | 00405-7&sz=64)
cell.com | David Hsiehchen |Andrew Elliott |Joanne Xiu |Andreas Seeber |Wafik El-Deiry |Emmanuel S. Antonarakis | +12 more
1Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA2Harold C.
-
Nov 14, 2024 | 
nature.com | Alireza Abdshah |Rana R. McKay
AbstractAndrogen receptor stimulation by testosterone and dihydrotestosterone is crucial for prostate cancer progression. Despite the initial effectiveness of androgen deprivation therapy (ADT), castration-resistant prostate cancer eventually develops in most men.
-
Oct 30, 2024 | 
targetedonc.com | Rana R. McKay
Rana R. McKay, MD, professor of medicine and urology at UC San Diego School of Medicine, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event. At the event, she discussed data such as an update from the CheckMate 274 trial (NCT02632409) of nivolumab (Opdivo) vs placebo as adjuvant therapy for MIBC.
-
Oct 21, 2024 | 
targetedonc.com | Rana R. McKay
October 21, 2024Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years. What unmet needs persist in first-line treatment of metastatic renal cell carcinoma (mRCC)? What advances do you anticipate in tyrosine kinase inhibitor–based therapies or other approaches for mRCC in the coming years?
-
Oct 21, 2024 | 
targetedonc.com | Rana R. McKay
October 21, 2024Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients. How do efficacy outcomes, such as overall survival and progression-free survival, compare with tolerability and quality of life in your decision-making process for first-line metastatic renal cell carcinoma treatment?
-
Oct 14, 2024 | 
targetedonc.com | Rana R. McKay
October 14, 2024Panelists discuss how the management of adverse events differs between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor plus TKI (ICI+TKI) combinations, including any notable differences in adverse effect profiles among various ICI plus TKI regimens used in treating metastatic renal cell carcinoma.
-
Oct 7, 2024 | 
targetedonc.com | Rana R. McKay
October 7, 2024Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.
